SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/55744"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/55744" > Does albuminuria pr...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003555naa a2200565 4500
001oai:gup.ub.gu.se/55744
003SwePub
008240528s2006 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/557442 URI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ibsen, H.4 aut
2451 0a Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study
264 1c 2006
520 a OBJECTIVE: Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events. RESEARCH DESIGN AND METHODS: In 1,063 patients with diabetes, hypertension, and left ventricular hypertrophy, UACR was measured for a mean of 4.7 years. The primary composite end point included cardiovascular death, myocardial infarction, and stroke. Cox models were run including and excluding baseline and time-varying UACR. RESULTS: Increasing baseline albuminuria related to increased risk for cardiovascular events. Reductions in UACR at years 1 and 2 were approximately 33% for losartan vs. 15% for atenolol (P < 0.001). Benefits of losartan seem to be most prominent in patients with the highest level of baseline UACR, although treatment by albuminuria interaction was only significant for total mortality. Approximately one-fifth of the superiority of losartan was explained by the greater reduction of albuminuria. Risk of the primary end point was related to the in-treatment UACR. CONCLUSIONS: Lowering of albuminuria in patients with hypertension and diabetes appears to be beneficial and should be the subject of additional study in future clinical trials.
653 a Aged
653 a Aged
653 a 80 and over
653 a Albuminuria/*epidemiology/urine
653 a Antihypertensive Agents/*therapeutic use
653 a Atenolol/*therapeutic use
653 a Cardiovascular Diseases/*etiology/prevention & control
653 a Creatinine/urine
653 a Diabetes Mellitus/drug therapy/*epidemiology
653 a Female
653 a Humans
653 a Hypertension/drug therapy/*epidemiology
653 a Hypertrophy
653 a Left Ventricular/drug therapy/*epidemiology
653 a Losartan/*therapeutic use
653 a Male
653 a Middle Aged
653 a Predictive Value of Tests
653 a Risk
653 a Treatment Outcome
7001 a Olsen, M. H.4 aut
7001 a Wachtell, K.4 aut
7001 a Borch-Johnsen, K.4 aut
7001 a Lindholm, L. H.4 aut
7001 a Mogensen, C. E.4 aut
7001 a Dahlöf, Björn,d 1953u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine4 aut0 (Swepub:gu)xdahbj
7001 a Snapinn, S. M.4 aut
7001 a Wan, Y.4 aut
7001 a Lyle, P. A.4 aut
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin4 org
7730 t Diabetes Careg 29:3, s. 595-600q 29:3<595-600x 0149-5992
8564 8u https://gup.ub.gu.se/publication/55744

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy